Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D8VJT5
|
|||
| Drug Name |
ZEN-3694
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Prostate cancer [ICD-11: 2C82.0; ICD-9: 185] | Phase 2 | [1] | |
| Company |
Zenith Epigenetics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Bromodomain and extraterminal domain protein (BET) | Target Info | Inhibitor | [2] |
| KEGG Pathway | SNARE interactions in vesicular transport | |||
| Reactome | COPII (Coat Protein 2) Mediated Vesicle Transport | |||
| WikiPathways | miR-targeted genes in squamous cell - TarBase | |||
| miR-targeted genes in muscle cell - TarBase | ||||
| miR-targeted genes in lymphocytes - TarBase | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04471974) ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Zenith Epigenetics. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.